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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Background and objectives: Peroperative myocardial infarction (MI) is the most common 
cause of morbidity and mortality. What is the role of general anesthesia in this process? Is gen-
eral anesthesia a risk for myocardial infarction? The present study was designed to determine 
whether the measurement of serum levels of cardiac troponin I (cTnI), a highly sensitive and 
speciﬁ  c marker for cardiac injury, would help establish the diagnosis of myocardial infarction 
in two different types of anesthesia.
Method: Elective abdominal hysterectomy was planned with the permission of the ethic com-
mittee in 40 patients who were 20–45 years range, in ASA-I group, and have a Goldman Cardiac 
Risk Index-0. The patients were divided into two groups. Isoﬂ  urane + N2O was administrated 
to ﬁ  rst group, and Propofol + Fentanyl to second group. cTnI levels were determined before 
anesthesia, after induction before surgery and 9 hours after the second period respectively.
Results: There was no signiﬁ  cant difference between the groups by the means of demographic 
properties, hemodynamic parameters and cTnI levels, and the cTnI levels were determined 
under the basal levels in all samples.
Conclusion: General anesthesia is not a risk for myocardial infarction to state eliminating risk 
factors and protection hemodynamia cardiac.
Keywords: cardiac troponin-I, myocardial infarction, isoﬂ  uran + N2O inhalation anesthesia, 
propofol + fentanyl intravenous anesthesia.
Introduction
Peroperative myocardial infarction (MI) which is detected by troponin I is the most 
common cause of morbidity and mortality (Adams et al 1994). What is the role of 
general anesthesia in this process? Is general anesthesia a risk for MI?
Anesthesia directly causes myocardial depression and also effects vascular tonus 
and myocardial contractibility by autonomic nervous system or by hypoxia, hypercap-
nia, and acidosis depress myocardium (Corial et al 1998; Miller et al 1988). Apart from 
anesthesia, complications such as surgery, bleeding, infection, fever, and emboli also 
increase cardiac load. In the absence of cardiac disease, either myocardium may not 
tolerate this additional stress and failure or ischemia may develop. In order to decrease 
postoperative mortality and morbidity, risks must be determined and prevented.
We tried to determine the cardiac injury, in three periods (pre-, per- and postopera-
tive), and we realized that it has no side effects after using isoﬂ  uran + N2O inhalation Vascular Health and Risk Management 2006:2(4) 465–475
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and propofol + fentanyl intravenous anesthesia in healthy 
patients who underwent noncardiac surgery.
Method
The study was conducted with the permission of the faculty 
etiquette committee. All patients were informed and con-
sented. Elective abdominal hysterectomy was planned in 
40 patients who were 20–45 years range, in ASA-I group and 
Goldman Cardiac Risk Index-0. The patients were admitted 
to operation room without premedication, monitorization, 
and vital parameters (TA, pulse, arterial O2 saturation) were 
recorded. Two venous catheters were placed on each hand, 
blood samples were taken from one, and ﬂ  uid was given into 
the other. The patients were divided into two groups. Each 
group was formed by 20 patients. Inhalation anesthesia was 
administrated to the ﬁ  rst group, and intravenous anesthe-
sia to the second. After induction with thiopental sodium 
(4–7 mg/kg) + fentanyl (1 µg/kg), inhalation anesthesia was 
maintained by isoﬂ  uran 1.5% + N2O/O2 (50%/50%). In the 
second group, after induction with propofol (3 mg/kg) and 
fentanyl (5 µg/kg), anesthesia was maintained by propofol 
(0.2 mg/kg/min) and fentanyl ( 0.2 µg/kg/min). The patients 
in this group were ventilated by 50% O2 and 50% air. Muscle 
relaxation was provided by vecuronium bromide (0.1 mg/kg) 
in both groups, and mechanical ventilation was applied as 
follows: VT: 8−10 ml/kg, f: 10−12 min, Pmax 20−30 mbar, 
PEEP: O mbar, T1/E: 1/1.7 monitorization and ventilation was 
obtained from DRÄGER Cato 8040 anesthesia machine and 
perfusion by Compact B BRAUN perfuser.
Three blood samples were taken from patients, before 
anesthesia, after induction before surgery and 9 hours 
after second period. Blood samples were taken into sterile 
tubes which did not contain EDTA and heparin in order 
to avoid low results, and they were centrifuged and stored 
in −20 °C.
Cardiac troponin I levels were calculated by ng/ml with 
solid phase, two-site chemluminescent immunometric assay 
method in Immulite Automated Analyser. Normal Range: 
 0.4ng/ml. Statistical analysis was performed by SPSS 
for Windows (Microsoft, Redmond, Washington DC). All 
results are expressed as mean ±SD except as stated otherwise. 
p values under 0.05 (p   0.05) were accepted statistically 
signiﬁ  cant. T-test was used as the groups have parametric 
and independent conditions.
Results
Groups were similar according to age, body weight and 
gender (Table 1).
Except for the pulse rates under anesthesia, there was 
no difference in the preanaesthetic and anaesthetic hemo-
dynamic parameters of two groups (p   0.05) (Table 2). 
The pulse rates difference under anesthesia was attributed 
to the bradycardic effects of anaesthetic agent that was used 
in intravenous group.
The cTnI levels were presented in Table 3. With p   0.05, 
there was no difference in troponin levels between groups.
As the value for the troponin levels between preanaesthetic/
anaesthetic and anaesthetic/postanaesthetic was p   0.05, 
there was no signiﬁ  cant difference found (Table 4).
Discussion
We tried to determine the cardiac injury rate using cTnI 
blood levels through two different anesthesia techniques in 
preanaesthesic, anaesthetic, and postanaesthetic (9th hour) 
periods. Patients were selected from ASA-I group who have 
no cardiac risk factor, no drug usage, without metabolic and 
endocrine disorder. They were divided into the inhalation and 
intravenous group randomly. Demographically, no differ-
ence was found between two groups. Isoﬂ  uran + N2O were 
preferred because of minimal cardiac depressive effects and 
propofol + fentanyl for best suppression in stress response. 
Muscle relaxation was ensured by vecuronium bromide in 
both groups, which had no cardiac side effects. Anesthetic 
pulse rates were determined lower comparing the hemody-
namic parameters of both groups. This contributed to the 
vagal effect of fentanyl. As arterial blood pressure and O2 
saturation were not different at the rare time, it was estimated 
that this effect did not inﬂ  uence cardiac hemodynamia. Tro-
ponin I blood samples collected in three periods was found 
in basal levels. There was no signiﬁ  cant difference between 
the groups statistically.
Under physiological conditions, myocardium works to 
balance the O2 supply and needs O2, but in critical states such 
as anesthesia, myocardium exposes physiologic and phar-
macologic distress. The increased O2 need is compensated 
by tachycardia, increased contractility, and left ventricle 
end-diastolic pressure. As myocardium satisfies the O2 
need, in diastole this mechanism may cause ischemic attacks 
Table 1 Demographic properties (mean ± standard error)
Group Inhalation  Intravenous    p
 (n  = 10)  (n = 10)
Age (year)  39.27 ± 8.45  40.27 ± 1.70  0.747
Body weight (kg)  68.64 ± 1.74  69.73 ± 3.3  0.778
Gender (f/m)  20/0  20/0Vascular Health and Risk Management 2006:2(4) 465–475
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Is general anesthesia a risk for myocardium?
and myocardial injury. An anesthetic agent causes imbal-
ance in this compensation mechanism. They may depress 
myocardium directly or changing the vascular tonus and 
myocardial contractility in the autonomic nervous system, 
changing cardiac rhythm-rate or hypoxia, hypercapnia and 
acidosis. Apart from anesthesia, cardiac load is increased by 
surgery, bleeding, infection, fever, and complications such as 
pulmonary emboli. Especially, among the older population, 
the incidence of ischemic heart disease in intensive care unit 
is higher. Developing surgery and anesthetic opportunities 
ensure more patients are operated upon and their mean 
lifetime increases. This means more patients with cardiac 
problems and anesthesia administration. Either in the absence 
of cardiac disease, anesthetic and surgical additional stress 
may cause failure ischemia (Coriat et al 1990).
The most common complication is myocardial necrosis 
and 3%−5% of patients are seen under risk. Many of them 
are silent subendocardial lesions, but in a shorter time, this 
may have life threatening effect on surgery patients. Car-
diac evens usually occur after 48 hours from surgery. In the 
early postoperative period, increased left ventricle load and 
metabolic disorders were common, especially, the release 
of cathelocoliginergic mediators and increased hypercoagu-
ability related to the effects of anesthesia on circulation and 
surgery stimulus. This change demolishes myocardial energy 
balance and causes left ventricular failure development. For 
this reason, in order to reduce mortality and morbidity related 
to cardiac complications, risks must be determined and mea-
sures must be taken (De Hert et al 1989, 2003; Lowenstein 
1989; Priebe 2005; Weitz 2001).
In the past 20 years, creatinine kinase mb (CK-MB) iso-
enzyme, which has been issued as a marker for this purpose, 
may also be positive in traumatic injuries, renal insufﬁ  ciency, 
strokes and mypathies, has not been informative. In diagnosis 
Wu et al suggest that after 6−24 hours later from the onset of 
acute myocardial infarction (AMI) CK-MB has great sensitiv-
ity but in 24−48 hours the sensitivity is reduced (Wu 1996; 
Benoit 2001). Although myoglubin is valuable in the early 
period, it is not speciﬁ  c to cardiac injury. Cummins et al (1987) 
reported cTnl releasing in AMI. Many acceptable studies were 
performed about the sensitivity and specify of cTnl (Adams 
et al 1990, 1993) Diagnosis and postoperative management 
is presently based on assessment of cTnI (Coriat 2001). The 
European and American Cardiology Societies (ESC/ACC 
2000) have established cTnI as the gold standard for diagnosis 
of AMI and risk stratiﬁ  cation for adverse cardiac events.
Experimental and clinical studies have extensively shown 
that all volatile anesthetic agents decrease myocardial load-
ing conditions and contractility. Even the newer inhalational 
agents such as desﬂ  urane and sevoﬂ  urane seem to exhibit a 
similar dose-dependent depression of myocardial function 
(De Hert et al 2001). Those depressant effects decrease 
myocardial oxygen demand and may, therefore, have a 
beneﬁ  cial role on the myocardial oxygen balance during 
myocardial ischemia. Recently, experimental evidence has 
demonstrated that in addition to these indirect protective 
effects, volatile anesthetic agents also have direct protec-
tive properties against reversible and irreversible ischemic 
myocardial damage (De Hert 2006).
As a result, general anesthesia is not a risk for MI to date, 
but eliminates risk factors and protection against cardiac 
hemodynamia.
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